Gilead locks in Daniel O'Day as CEO, tapping the Roche vet to rejuvenate growth
The suspense over who will succeed John Milligan at Gilead has finally ended.
Daniel O’Day, current CEO of Roche’s Pharma division, has been tapped for the top job, Gilead announced days before Milligan is set to depart from his corner office.
O’Day’s appointment ushers in a new era for the Foster City, CA-based big biotech, which Milligan and his predecessor, John Martin, ran for nearly three decades, creating an HIV powerhouse and an industry-dominating hepatitis C franchise. In recent years, however, it’s seen its revenue shrink as competition heats up and the painless cure effectively downsized the market.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.